Real-World check: is talzenna safe for advanced breast cancer?

NCT ID NCT04982848

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will track 600 people in Korea with advanced breast cancer who are already being prescribed Talzenna. Researchers will watch for side effects and see how well the drug works in everyday medical practice, not in a strict research setting. The goal is to confirm the drug's safety and effectiveness after it has been approved for use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talzenna (talazoparib)
What this could lead to: If successful, this study will confirm that Talzenna is safe and effective for treating advanced breast cancer in everyday medical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already prescribed the drug, which may limit generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hereditary breast ovarian cancer syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.